Villepinte – January 28, 2026 – At the upcoming European Congress of Radiology (ECR) in Vienna, March 4–8, 2026, Guerbet reaffirms its commitment to innovation in medical imaging, and its support for the attractiveness of the healthcare ecosystem:
In 2026, Guerbet celebrates its 100th anniversary. On this occasion, the Group will unveil the visual identity created for its centenary, reflecting a century of innovation in medical imaging and reaffirming its commitment to advancing radiology. This new identity will be showcased for the first time at ECR 2026, marking a symbolic milestone in Guerbet’s history and illustrating its continuous ambition to shape the future of diagnostic and interventional imaging.
Guerbet will showcase Elucirem™ (Gadopiclenol), our macrocyclic gadolinium-based contrast agent. If approved by the European Commission, Elucirem™ (gadopiclenol) will be indicated in adults and in children from birth, for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
For these indications, an MRI examination with Elucirem™(gadopiclenol) requires half the conventional gadolinium dose compared to that required with existing nonspecific contrast agents, thus answering a major concern of practitioners about gadolinium exposure.[1], [2], [3]
A major step forward in improving diagnostic imaging for young patients reflects Guerbet’s continued commitment to innovation and patient safety.
A dedicated patient case space will highlight the critical role of Real-World Evidence (RWE) in advancing radiology practices, demonstrating how real-life data helps improve patient care and guide clinical decision-making.
France will be honored at this edition of ECR, and Guerbet is proud to contribute to promoting French excellence in healthcare. Our booth will host the “French Pavilion”under the aegis of the French Healthcare initiative, fostering dialogue and cooperation among companies, institutions, and healthcare stakeholders to showcase innovative health solutions worldwide.
Meet Guerbet at ECR 2026:📍 Austria Center Vienna – Booth 507 HALL X5 📅 March 4–8, 2026
For more information about our innovations and commitments: www.guerbet.com
About Guerbet
At Guerbet, we build lasting connections to enable better living. This is our Purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging.
Pioneers in contrast agents for 98 years, with 2,905 employees worldwide, we continuously innovate and dedicate 9% of our revenue to Research & Development across four centers in France and the United States. Guerbet (GBT) is listed on Euronext Paris, Compartment B, and achieved €841 million in revenue in 2024.
For more information, please visit : www.guerbet.com
GBCA: Gadolinium-Based Contrast Agent
1 PRAC, European Medicines Agency, 2017
2 FDA Drug Safety Communication, 2017
3 Brunjes et al. Water Research, 2020
Contact:
Matthieu BRUNEAU – Global corporate communication manager
Email: [email protected]
Phone: +33 6 78 83 89 96